Recent News

• 03.24.2026 - Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
• 03.23.2026 - Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
• 03.04.2026 - Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
• 03.02.2026 - Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
• 02.18.2026 - Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
• 02.09.2026 - Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
• 01.23.2026 - Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
• 01.21.2026 - Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Recent Filings

• 03.20.2026 - 8-K Current report
• 03.05.2026 - 3 Initial statement of beneficial ownership of securities
• 03.04.2026 - 8-K Current report
• 03.04.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.04.2026 - EX-99.1 EX-99.1
• 03.04.2026 - 8-K Current report
• 03.04.2026 - EX-99.1 EX-99.1
• 03.04.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 02.09.2026 - 8-K Current report
• 01.30.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors